Upstream Bio receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Metrics to compare | UPB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipUPBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −1.7x | −0.2x | |
PEG Ratio | 0.05 | −0.15 | 0.00 | |
Price/Book | 0.5x | 2.3x | 2.6x | |
Price / LTM Sales | 38.6x | 15.5x | 2.7x | |
Upside (Analyst Target) | - | 106.6% | 69.6% | |
Fair Value Upside | Unlock | 7.5% | 11.7% | Unlock |
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.